Efavirenz (BioDeep_00000003056)

 

Secondary id: BioDeep_00000406137

human metabolite blood metabolite Volatile Flavor Compounds


代谢物信息卡片


6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one

化学式: C14H9ClF3NO2 (315.027388)
中文名称: 依法韦仑
谱图信息: 最多检出来源 Homo sapiens(blood) 20%

分子结构信息

SMILES: C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F
InChI: InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1

描述信息

Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors
D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065688 - Cytochrome P-450 CYP2C9 Inhibitors
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D065693 - Cytochrome P-450 Enzyme Inducers > D065695 - Cytochrome P-450 CYP2B6 Inducers
D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent
CONFIDENCE standard compound; EAWAG_UCHEM_ID 3292
CONFIDENCE standard compound; INTERNAL_ID 8518

同义名列表

19 个代谢物同义名

6-Chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one; (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one; (S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one; (-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one; Merck sharp and dohme brand OF efavirenz; Bristol-myers squibb brand OF efavirenz; United drug brand OF efavirenz; Du pont brand OF efavirenz; Efavirenz, (S)-isomer; Efavirenz, (R)-isomer; Efavirenz; DMP-266; DMP 266; Stocrin; Sustiva; EFV; Efavirenz



数据库引用编号

31 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Chunmei Wang, Xiaoli Yu, Yingchun Ke, Yanhua Fu, Yanhe Luo, Ying Li, Yanmei Bi, Xingqiong Chen, Linghua Li, Xiuhong Zhao, Zhong Chen. Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study. Antimicrobial agents and chemotherapy. 2024 Apr; 68(4):e0166823. doi: 10.1128/aac.01668-23. [PMID: 38483175]
  • Chloe Orkin, Jean-Michel Molina, Pedro Cahn, Johannes Lombaard, Khuanchai Supparatpinyo, Sushma Kumar, Havilland Campbell, Hong Wan, Valerie Teal, Zhi Jin Xu, Ernest Asante-Appiah, Peter Sklar, Hedy Teppler, Rima Lahoulou. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials. The lancet. HIV. 2024 Feb; 11(2):e75-e85. doi: 10.1016/s2352-3018(23)00258-8. [PMID: 38141637]
  • Abdurezak Ahmed Abdela, Helen Yifter, Ahmed Reja, Aster Shewaamare, Ighovwerha Ofotokun, Wondwossen Amogne Degu. Prevalence and risk factors of metabolic syndrome in Ethiopia: describing an emerging outbreak in HIV clinics of the sub-Saharan Africa - a cross-sectional study. BMJ open. 2023 12; 13(12):e069637. doi: 10.1136/bmjopen-2022-069637. [PMID: 38070936]
  • Xingguo Miao, Hui Ye, Xiaoya Cui, Xiuxiu Guo, Feifei Su. Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation. Nutrition research (New York, N.Y.). 2023 Sep; 119(?):119-131. doi: 10.1016/j.nutres.2023.09.006. [PMID: 37826994]
  • Kiamu Kurosawa, Masataka Nakano, Itsuki Yokoseki, Mai Nagaoka, Seiya Takemoto, Yoshiyuki Sakai, Kaoru Kobayashi, Yasuhiro Kazuki, Tatsuki Fukami, Miki Nakajima. ncBAF enhances PXR-mediated transcriptional activation in the human and mouse liver. Biochemical pharmacology. 2023 Aug; 215(?):115733. doi: 10.1016/j.bcp.2023.115733. [PMID: 37543347]
  • Alejandro O Sodero, Valeria C Castagna, Setiembre D Elorza, Sara M Gonzalez-Rodulfo, María A Paulazo, Jimena A Ballestero, Mauricio G Martin, María Eugenia Gomez-Casati. Phytosterols reverse antiretroviral-induced hearing loss, with potential implications for cochlear aging. PLoS biology. 2023 Aug; 21(8):e3002257. doi: 10.1371/journal.pbio.3002257. [PMID: 37619212]
  • Daniela Zizioli, Sara Ferretti, Giorgio Tiecco, Luca Mignani, Eugenio Monti, Francesco Castelli, Eugenia Quiros-Roldan, Isabella Zanella. Comparison of Efavirenz and Doravirine Developmental Toxicity in an Embryo Animal Model. International journal of molecular sciences. 2023 Jul; 24(14):. doi: 10.3390/ijms241411664. [PMID: 37511423]
  • P N Kunene, P N Mahlambi. Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits. Environmental pollution (Barking, Essex : 1987). 2023 Feb; 319(?):121004. doi: 10.1016/j.envpol.2023.121004. [PMID: 36608725]
  • Mohammed Jemal, Tewodros Shibabaw Molla, Markeshaw Tiruneh G Medhin, Endeshaw Chekol Abebe, Tadesse Asmamaw Dejenie. Blood glucose level and serum lipid profiles among people living with HIV on dolutegravir-based versus efavirenz-based cART; a comparative cross-sectional study. Annals of medicine. 2023; 55(2):2295435. doi: 10.1080/07853890.2023.2295435. [PMID: 38118463]
  • Adem Simsek, Oguz Karabay, Ertugrul Guclu, Hande Toptan. Comparison of Metabolic Effects of Three Different Treatment Combinations with Retrospective Real-life Data in People Living with HIV. Current HIV research. 2023; 21(5):314-322. doi: 10.2174/011570162x266922231107094649. [PMID: 37990894]
  • M A Hamed, R E Akhigbe, A O Aremu, A F Odetayo. Zinc normalizes hepatic lipid handling via modulation of ADA/XO/UA pathway and caspase 3 signaling in highly active antiretroviral therapy-treated Wistar rats. Chemico-biological interactions. 2022 Dec; 368(?):110233. doi: 10.1016/j.cbi.2022.110233. [PMID: 36309141]
  • Liqin Sun, Yun He, Liumei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Qiaoli Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, Man Rao, Xinyun Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu. Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China. Journal of acquired immune deficiency syndromes (1999). 2022 10; 91(S1):S8-S15. doi: 10.1097/qai.0000000000003040. [PMID: 36094509]
  • Rohini Kharwade, Sachin More, Elizabeth Suresh, Amol Warokar, Nilesh Mahajan, Ujwala Mahajan. Improvement in Bioavailability and Pharmacokinetic Characteristics of Efavirenz with Booster Dose of Ritonavir in PEGylated PAMAM G4 Dendrimers. AAPS PharmSciTech. 2022 Jun; 23(6):177. doi: 10.1208/s12249-022-02315-8. [PMID: 35750994]
  • Zelalem Petros, Abiy Habtewold, Eyasu Makonnen, Eleni Aklillu. Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity. Scientific reports. 2022 06; 12(1):9698. doi: 10.1038/s41598-022-14032-0. [PMID: 35690682]
  • M A Ortíz-Rodríguez, J Oaxaca-Navarro, S I Patiño-Camacho, S García-Jiménez, M Déciga-Campos, M F Martínez-Salazar. Plasma levels of efavirenz and frequency of the CYP2B6 516G>T polymorphism in people living with HIV-1 in Mexico. Die Pharmazie. 2022 Jun; 77(6):191-195. doi: 10.1691/ph.2022.2382. [PMID: 35751161]
  • Lauren Jennings, Tracy Kellermann, Matthew Spinelli, Zukiswa Nkantsu, Dolphina Cogill, Marije van Schalkwyk, Eric Decloedt, Gert van Zyl, Catherine Orrell, Monica Gandhi. Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS research and human retroviruses. 2022 06; 38(6):455-462. doi: 10.1089/aid.2021.0135. [PMID: 34779228]
  • Cecilia M Shikuma, Thuy Le, Thao Vu Phuong, Glen M Chew, Van Vinh Chau Nguyen, Trieu Ly Vo, Chathura Siriwardhana, Dominic Chow, Hayk Ghukasyan, Nath Limpruttidham, Thomas Premeaux, Louie Mar Gangcuangco, Robert Paul, Lishomwa C Ndhlovu. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam. AIDS research and human retroviruses. 2022 06; 38(6):441-450. doi: 10.1089/aid.2021.0076. [PMID: 34861767]
  • Monkgomotsi J Maseng, Leabaneng Tawe, Prisca K Thami, Sikhulile Moyo, Ishmael Kasvosve, Vladimir Novitsky, Max Essex, Gianluca Russo, Simani Gaseitsiwe, Giacomo M Paganotti. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana. Medicine. 2022 Apr; 101(17):e29066. doi: 10.1097/md.0000000000029066. [PMID: 35512066]
  • Jing Xiao, Jiang Xiao, Ying Liu, Bei Li, Leidan Zhang, Junyan Han, Hongxin Zhao. Efficacy and safety of Efavirenz 400 mg-based regimens switching from 600 mg-based regimens in people living with HIV with virological suppression in China: a randomized, open-label, non-inferiority study. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2022 Apr; 117(?):48-55. doi: 10.1016/j.ijid.2022.01.051. [PMID: 35108610]
  • David W Haas, Rosie Mngqibisa, Jose Francis, Helen McIlleron, Jennifer A Robinson, Michelle A Kendall, Paxton Baker, Sajeeda Mawlana, Sharlaa Badal-Faesen, Francis Angira, Ayotunde Omoz-Oarhe, Wadzanai P Samaneka, Paolo Denti, Susan E Cohn. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenetics and genomics. 2022 01; 32(1):24-30. doi: 10.1097/fpc.0000000000000448. [PMID: 34369424]
  • Wondmagegn Tamiru Tadesse, Birhanemeskel T Adankie, Workineh Shibeshi, Wondwossen Amogne, Eleni Aklillu, Ephrem Engidawork. Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy. PloS one. 2022; 17(1):e0262604. doi: 10.1371/journal.pone.0262604. [PMID: 35045105]
  • Lisa M Frenkel, R Leavitt Morrison, Trevon L Fuller, Maria Isabel Gouvêa, Maria de Lourdes Benamor Teixeira, Robert W Coombs, David E Shapiro, Mark Mirochnick, Roslyn Hennessey, Kyle Whitson, Nahida Chakhtoura, Esaú C João. Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial. Journal of acquired immune deficiency syndromes (1999). 2021 12; 88(4):361-365. doi: 10.1097/qai.0000000000002771. [PMID: 34369908]
  • Xian-Min Meng, Zi-Ran Li, Xin-Yin Zheng, Yi-Xi Liu, Wan-Jie Niu, Xiao-Yan Qiu, Hong-Zhou Lu. Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2021 Dec; 167(?):105986. doi: 10.1016/j.ejps.2021.105986. [PMID: 34474119]
  • Selwyn J Hurwitz, Sijia Tao, Christina Gavegnano, Yong Jiang, Randall L Tressler, Athe Tsibris, Carlos Del Rio, Edgar T Overton, Michael M Lederman, Amy Kantor, Carlee Moser, James J Kohler, Jeffrey Lennox, Vincent C Marconi, Charles W Flexner, Raymond F Schinazi. Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study. Journal of clinical pharmacology. 2021 12; 61(12):1555-1566. doi: 10.1002/jcph.1930. [PMID: 34169526]
  • Musa Otieno Ngayo, Margaret Oluka, Wallace Dimbuson Bulimo, Faith Apolot Okalebo. Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya. Scientific reports. 2021 11; 11(1):22071. doi: 10.1038/s41598-021-01345-9. [PMID: 34764325]
  • Natália Bordin Andriguetti, Helena Katherina Van Schalkwyk, Daniel Thomas Barratt, Joseph Tucci, Paul Pumuye, Andrew Alexander Somogyi. Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and translational science. 2021 11; 14(6):2521-2531. doi: 10.1111/cts.13120. [PMID: 34415664]
  • Huan Xia, Xiao-Jie Huang, Yue Hu, Li-Ying Gao, Yue Wu, Hao Wu, Zhong-Fang Yan, Ping Ma. Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV. Chinese medical journal. 2021 Oct; 134(23):2850-2856. doi: 10.1097/cm9.0000000000001824. [PMID: 34653085]
  • Jessica Cusato, Massimo Tempestilli, Andrea Calcagno, Alessandra Vergori, Pierluca Piselli, Miriam Antonucci, Valeria Avataneo, Alice Palermiti, Stefania Notari, Andrea Antinori, Giovanni Di Perri, Chiara Agrati, Antonio D'Avolio. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz. Nutrients. 2021 Oct; 13(10):. doi: 10.3390/nu13103571. [PMID: 34684572]
  • Jesper Sundell, Emile Bienvenu, Angela Äbelö, Michael Ashton. Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV. The Journal of antimicrobial chemotherapy. 2021 10; 76(11):2950-2957. doi: 10.1093/jac/dkab258. [PMID: 34337654]
  • Jacinta N Nwogu, Monica Gandhi, Andrew Owen, Saye H Khoo, Babafemi Taiwo, Adeniyi Olagunju, Baiba Berzins, Hideaki Okochi, Regina Tallerico, Kevin Robertson, Chinedum P Babalola. Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria. AIDS (London, England). 2021 10; 35(12):1919-1927. doi: 10.1097/qad.0000000000002984. [PMID: 34115651]
  • Natália Bordin Andriguetti, Daniel T Barratt, Joseph Tucci, Paul Pumuye, Andrew A Somogyi. Instability of Efavirenz Metabolites Identified During Method Development and Validation. Journal of pharmaceutical sciences. 2021 10; 110(10):3362-3366. doi: 10.1016/j.xphs.2021.06.028. [PMID: 34175301]
  • Wangu Masenga, Giacomo Maria Paganotti, Kaelo Seatla, Simani Gaseitsiwe, Kwenga Sichilongo. A fast-screening dispersive liquid-liquid microextraction-gas chromatography-mass spectrometry method applied to the determination of efavirenz in human plasma samples. Analytical and bioanalytical chemistry. 2021 Oct; 413(25):6401-6412. doi: 10.1007/s00216-021-03604-0. [PMID: 34557941]
  • Wei-Chieh Huang, Chun-Kai Huang, Sung-Hsi Huang, Shu-Wen Lin, Shyh-Tyan Ou, Yi-Ting Chen, Ya-Wen Chen, Shu-Yuan Chang, Wen-Chun Liu, Hsin-Yun Sun, Chien-Ching Hung. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2021 Oct; 54(5):944-951. doi: 10.1016/j.jmii.2020.06.010. [PMID: 32675042]
  • Birgit E Watson, Kieran Atkinson, Kathleen Auyeung, Katherine A Baynes, Katherine J Lepik, Junine Toy, Paul Sereda, Rolando Barrios, Chanson J Brumme. Untimed Efavirenz Drug Levels After Switching From Brand to Generic Formulations: A Short Communication. Therapeutic drug monitoring. 2021 10; 43(5):701-705. doi: 10.1097/ftd.0000000000000876. [PMID: 33560098]
  • Jose Francis, Rosie Mngqibisa, Helen McIlleron, Michelle A Kendall, Xingye Wu, Kelly E Dooley, Cynthia Firnhaber, Catherine Godfrey, Susan E Cohn, Paolo Denti. A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. Clinical pharmacology and therapeutics. 2021 10; 110(4):1057-1065. doi: 10.1002/cpt.2324. [PMID: 34151439]
  • Ngah Kuan Chow, Sabariah Noor Harun, E-Jinq Wong, Lee Lee Low, Siti Maisharah Sheikh Ghadzi, Amer Hayat Khan. The association between cigarette smoking and efavirenz plasma concentration using the population pharmacokinetic approach. British journal of clinical pharmacology. 2021 10; 87(10):3756-3765. doi: 10.1111/bcp.14783. [PMID: 33608883]
  • Ken Ogasawara, Jeanelle Kam, Mark Thomas, Liangang Liu, Mary Liu, Yongjun Xue, Sekhar Surapaneni, Leonidas N Carayannopoulos, Simon Zhou, Maria Palmisano, Gopal Krishna. Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants. Cancer chemotherapy and pharmacology. 2021 09; 88(3):369-377. doi: 10.1007/s00280-021-04292-4. [PMID: 34019108]
  • Thalita Martins da Silva, Thiago da Silva Honorio, Marcelo Henrique da Cunha Chaves, Marcelo Dutra Duque, Lucio Mendes Cabral, Beatriz Ferreira de Carvalho Patricio, Helvécio Vinícius Antunes Rocha. In silico bioavailability for BCS class II efavirenz tablets using biorelevant dissolution media for IVIVR and simulation of formulation changes. Drug development and industrial pharmacy. 2021 Aug; 47(8):1342-1352. doi: 10.1080/03639045.2021.1991368. [PMID: 34622730]
  • Eleni Aklillu, Alimuddin Zumla, Abiy Habtewold, Wondwossen Amogne, Eyasu Makonnen, Getnet Yimer, Jürgen Burhenne, Ulf Diczfalusy. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients. British journal of pharmacology. 2021 08; 178(16):3294-3308. doi: 10.1111/bph.15309. [PMID: 33155675]
  • R E Akhigbe, M A Hamed, A O Aremu. HAART exacerbates testicular damage and impaired spermatogenesis in anti-Koch-treated rats via dysregulation of lactate transport and glutathione content. Reproductive toxicology (Elmsford, N.Y.). 2021 08; 103(?):96-107. doi: 10.1016/j.reprotox.2021.06.007. [PMID: 34118364]
  • Ketan Mahajan, Satish Rojekar, Dipen Desai, Smita Kulkarni, Gandhali Bapat, Smita Zinjarde, Pradeep Vavia. Layer-by-Layer Assembled Nanostructured Lipid Carriers for CD-44 Receptor-Based Targeting in HIV-Infected Macrophages for Efficient HIV-1 Inhibition. AAPS PharmSciTech. 2021 Jun; 22(5):171. doi: 10.1208/s12249-021-01981-4. [PMID: 34100170]
  • Sung-Hsi Huang, Wei-Chieh Huang, Shu-Wen Lin, Yu-Chung Chuang, Hsin-Yun Sun, Sui-Yuan Chang, Po-Hsien Kuo, Pei-Ying Wu, Wen-Chun Liu, Chieh Chiang, Chien-Ching Hung, Shan-Chwen Chang. Impact of Efavirenz Mid-dose Plasma Concentration on Long-Term Weight Change Among Virologically Suppressed People Living With HIV. Journal of acquired immune deficiency syndromes (1999). 2021 06; 87(2):834-841. doi: 10.1097/qai.0000000000002650. [PMID: 33587507]
  • Danilo César Galindo Bedor, Noely Camila Tavares Cavalcanti Bedor, João Gomes Pontes Neto, Lucas José de Alencar Danda, Flávio Martins de Oliveira, Guilherme Henrique Onório de Oliveira, José Lamartine Soares Sobrinho, Eric Beyssac, Whocely Victor de Castro, Davi Pereira de Santana. Characterization, in vitro dissolution, and pharmacokinetics of different batches of efavirenz raw materials. Drug development and industrial pharmacy. 2021 May; 47(5):725-734. doi: 10.1080/03639045.2021.1934860. [PMID: 34038291]
  • Chenai Sheilla Mutiti, Nyasha Nicole Kapungu, Comfort Ropafadzo Kanji, Nadina Stadler, Julia Stingl, Charles Nhachi, James Hakim, Collen Masimirembwa, Roslyn Stella Thelingwani. Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir. Pharmacology research & perspectives. 2021 05; 9(3):e00769. doi: 10.1002/prp2.769. [PMID: 33929078]
  • Kamunkhwala Gausi, Lubbe Wiesner, Jennifer Norman, Carole L Wallis, Carolyne Onyango-Makumbi, Tsungai Chipato, David W Haas, Renee Browning, Nahida Chakhtoura, Grace Montepiedra, Lisa Aaron, Katie McCarthy, Sarah Bradford, Tichaona Vhembo, Lynda Stranix-Chibanda, Gaerolwe R Masheto, Avy Violari, Blandina T Mmbaga, Linda Aurpibul, Ramesh Bhosale, Neetal Nevrekhar, Vanessa Rouzier, Enid Kabugho, Mercy Mutambanengwe, Vongai Chanaiwa, Mandisa Nyati, Tsungai Mhembere, Fuanglada Tongprasert, Anneke Hesseling, Katherine Shin, Bonnie Zimmer, Diane Costello, Patrick Jean-Philippe, Timothy R Sterling, Gerhard Theron, Adriana Weinberg, Amita Gupta, Paolo Denti. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clinical pharmacology and therapeutics. 2021 04; 109(4):1034-1044. doi: 10.1002/cpt.2044. [PMID: 32909316]
  • Tahir Ali, Samia Hannaoui, Satish Nemani, Waqas Tahir, Irina Zemlyankina, Pearl Cherry, Su Yeon Shim, Valerie Sim, Hermann M Schaetzl, Sabine Gilch. Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice. Acta neuropathologica communications. 2021 04; 9(1):58. doi: 10.1186/s40478-021-01162-1. [PMID: 33795005]
  • Angela Shogbon Nwaesei, Pamela M Moye-Dickerson, Robin Henry Dretler. Efavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report. Journal of pharmacy practice. 2021 Apr; 34(2):319-324. doi: 10.1177/0897190019868358. [PMID: 31451051]
  • Mark Nelson, Alan Winston, Andrew Hill, Rosie Mngqibisa, Ayesha Bassa, Chloe Orkin, Mohammed Rassool, Anthony Rodgers, Valerie Teal, Sushma Kumar, Hedy Teppler. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS (London, England). 2021 04; 35(5):759-767. doi: 10.1097/qad.0000000000002804. [PMID: 33587439]
  • Fadhel A Alomar, Chengju Tian, Prasanta K Dash, JoEllyn M McMillan, Howard E Gendelman, Santhi Gorantla, Keshore R Bidasee. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral research. 2021 03; 187(?):104975. doi: 10.1016/j.antiviral.2020.104975. [PMID: 33450312]
  • Joseph Ipe, Rudong Li, Ingrid F Metzger, Jessica Bo Li Lu, Brandon T Gufford, Zeruesenay Desta, Yunlong Liu, Todd C Skaar. Circulating miRNAs as Biomarkers for CYP2B6 Enzyme Activity. Clinical pharmacology and therapeutics. 2021 02; 109(2):485-493. doi: 10.1002/cpt.2018. [PMID: 32772362]
  • Ling Xu, Wenxiu Peng, Xiaojing Song, Yanling Li, Yang Han, Ting Zhu, Qiang Fu, Xiaoli Du, Wei Cao, Taisheng Li. Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study. BMC infectious diseases. 2021 Jan; 21(1):112. doi: 10.1186/s12879-021-05802-8. [PMID: 33485301]
  • Atupele P Kapito-Tembo, Andy Bauleni, Austin Wesevich, Dennis Ongubo, Mina C Hosseinipour, Queen Dube, Patrick Mwale, Amanda Corbett, Victor Mwapasa, Sam Phiri. Growth and Neurodevelopment Outcomes in HIV-, Tenofovir-, and Efavirenz-Exposed Breastfed Infants in the PMTCT Option B+ Program in Malawi. Journal of acquired immune deficiency syndromes (1999). 2021 01; 86(1):81-90. doi: 10.1097/qai.0000000000002515. [PMID: 33027153]
  • Fernando Geldres-Molina, Alex Castañeda-Sabogal, Maryori M Hilario-Gómez, Joshuan J Barboza. Lipid profile levels in HIV-AIDS patients on treatment with efavirenz and atazanavir. Cohort study. Gaceta medica de Mexico. 2021; 157(4):384-390. doi: 10.24875/gmm.m21000579. [PMID: 35133341]
  • Manmeet Singh, Dilpreet Singh, Sundar Mahajan, Bilal Ahmed Sheikh, Neena Bedi. Polymeric Precipitation Inhibitor Assisted Supersaturable SMEDDS of Efavirenz Based on Experimental Observations and Molecular Mechanics. Current drug delivery. 2021; 18(4):513-530. doi: 10.2174/1567201817666200731165508. [PMID: 32735521]
  • David W Haas, Anthony T Podany, Yajing Bao, Susan Swindells, Richard E Chaisson, Noluthando Mwelase, Khuanchai Supparatpinyo, Lerato Mohapi, Amita Gupta, Constance A Benson, Paxton Baker, Courtney V Fletcher. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenetics and genomics. 2021 01; 31(1):17-27. doi: 10.1097/fpc.0000000000000417. [PMID: 32815870]
  • Erika Tyrberg, Arvid Edén, Jaran Eriksen, Staffan Nilsson, Carl Johan Treutiger, Anders Thalme, Åsa Mellgren, Magnus Gisslén, Lars-Magnus Andersson. Higher plasma drug levels in elderly people living with HIV treated with darunavir. PloS one. 2021; 16(2):e0246171. doi: 10.1371/journal.pone.0246171. [PMID: 33539440]
  • Agnieszka Matuszewska, Beata Nowak, Anna Nikodem, Diana Jędrzejuk, Danuta Szkudlarek, Krzysztof Zduniak, Jarosław Filipiak, Marta Sznadruk-Bender, Tomasz Tomkalski, Ireneusz Ceremuga, Marek Bolanowski, Adam Szeląg. Effects of efavirenz and tenofovir on bone tissue in Wistar rats. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2020 11; 29(11):1265-1275. doi: 10.17219/acem/127684. [PMID: 33269812]
  • Dhanashree H Surve, Yugandhara B Jirwankar, Vikas D Dighe, Anil B Jindal. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and In Vivo Biodistribution. Molecular pharmaceutics. 2020 10; 17(10):3990-4003. doi: 10.1021/acs.molpharmaceut.0c00773. [PMID: 32808785]
  • Alexandra Calmy, Tamara Tovar Sanchez, Charles Kouanfack, Mireille Mpoudi-Etame, Sandrine Leroy, Ségolène Perrineau, Martial Lantche Wandji, Darius Tetsa Tata, Pierette Omgba Bassega, Thérèse Abong Bwenda, Marie Varloteaux, Marcel Tongo, Eitel Mpoudi-Ngolé, Alice Montoyo, Noémie Mercier, Vincent LeMoing, Martine Peeters, Jacques Reynes, Eric Delaporte. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. The lancet. HIV. 2020 10; 7(10):e677-e687. doi: 10.1016/s2352-3018(20)30238-1. [PMID: 33010241]
  • A Dravid, T P Betha, A K Sharma, R Gawali, U Mahajan, M Kulkarni, C Saraf, S Kore, M Dravid, N Rathod. Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibitor-containing first-line antiretroviral therapy in Pune, India. HIV medicine. 2020 10; 21(9):578-587. doi: 10.1111/hiv.12912. [PMID: 33021066]
  • Willem D F Venter, Simiso Sokhela, Bryony Simmons, Michelle Moorhouse, Lee Fairlie, Nkuli Mashabane, Celicia Serenata, Godspower Akpomiemie, Masebole Masenya, Ambar Qavi, Nomathemba Chandiwana, Kaitlyn McCann, Shane Norris, Matthew Chersich, Gary Maartens, Samanta Lalla-Edward, Alinda Vos, Polly Clayden, Elaine Abrams, Natasha Arulappan, Andrew Hill. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet. HIV. 2020 10; 7(10):e666-e676. doi: 10.1016/s2352-3018(20)30241-1. [PMID: 33010240]
  • P A Makoni, K W Kasongo, R B Walker. Preformulation studies of efavirenz with lipid excipients using thermal and spectroscopic techniques. Die Pharmazie. 2020 09; 75(9):417-423. doi: 10.1691/ph.2020.0053. [PMID: 32797766]
  • Charlotte S Hakkers, Anne Marie Hermans, Erik M van Maarseveen, Charlotte E Teunissen, Inge M W Verberk, Joop E Arends, Andy I M Hoepelman. High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. Journal of neurovirology. 2020 08; 26(4):572-580. doi: 10.1007/s13365-020-00860-1. [PMID: 32524424]
  • Rong Chen, Jun Chen, Jingna Xun, Zhiliang Hu, Qiong Huang, Renfang Zhang, Corky Steinhart, Yinzhong Shen, Li Liu, Hongzhou Lu. Pharmacogenomics and pharmacokinetics of efavirenz 400 or 600 mg in 184 treatment-naive HIV-infected patients in China. Pharmacogenomics. 2020 08; 21(13):945-956. doi: 10.2217/pgs-2019-0169. [PMID: 32838647]
  • Wu Menghua, Zheng Xin, Liu Jianwei, Zhang Yu, Yao Qinwei. Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4+ T cell count. AIDS research and therapy. 2020 07; 17(1):46. doi: 10.1186/s12981-020-00301-3. [PMID: 32703286]
  • Jesper Sundell, Emile Bienvenu, David Janzén, Sofia Birgersson, Angela Äbelö, Michael Ashton. Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. Clinical pharmacology and therapeutics. 2020 07; 108(1):73-80. doi: 10.1002/cpt.1806. [PMID: 32017035]
  • Piyawat Chaivichacharn, Anchalee Avihingsanon, Weerawat Manosuthi, Sasiwimol Ubolyam, Siraprapa Tongkobpetch, Vorasuk Shotelersuk, Baralee Punyawudho. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand. Clinical therapeutics. 2020 07; 42(7):1234-1245. doi: 10.1016/j.clinthera.2020.04.013. [PMID: 32451120]
  • Adebanjo Jonathan Adegbola, Abutaima Rana, Babatunde Ayodeji Adeagbo, Rahman A Bolarinwa, Adeniyi Ebenezer Olagunju, Marco Siccardi, Andrew Owen, Oluseye Oladotun Bolaji. Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. Pharmacogenetics and genomics. 2020 07; 30(5):96-106. doi: 10.1097/fpc.0000000000000401. [PMID: 32209837]
  • Maria M Posada, Bridget L Morse, P Kellie Turner, Palaniappan Kulanthaivel, Stephen D Hall, Gemma L Dickinson. Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. Journal of clinical pharmacology. 2020 07; 60(7):915-930. doi: 10.1002/jcph.1584. [PMID: 32080863]
  • Louis Nyende, Robert Kalyesubula, Emmanuel Sekasanvu, Pauline Byakika-Kibwika. Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study. BMC nephrology. 2020 06; 21(1):232. doi: 10.1186/s12882-020-01873-y. [PMID: 32571236]
  • Daniel Atwine, Elisabeth Baudin, Thibaut Gelé, Winnie Muyindike, Kenneth Mworozi, Racheal Kyohairwe, Keneth Kananura, Patrick Orikiriza, Dan Nyehangane, Deborah K T Nanjebe, Valérie Furlan, Céline Verstuyft, Aurélie Barrail-Tran, Anne-Marie Taburet, Maryline Bonnet. Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. The Journal of antimicrobial chemotherapy. 2020 05; 75(5):1250-1258. doi: 10.1093/jac/dkz557. [PMID: 31999314]
  • Esaú C João, R Leavitt Morrison, David E Shapiro, Nahida Chakhtoura, Maria Isabel S Gouvèa, Maria de Lourdes B Teixeira, Trevon L Fuller, Blandina T Mmbaga, James S Ngocho, Boniface N Njau, Avy Violari, Ruth Mathiba, Zaakirah Essack, Jose Henrique S Pilotto, Luis Felipe Moreira, Maria Jose Rolon, Pedro Cahn, Sinart Prommas, Timothy R Cressey, Kulkanya Chokephaibulkit, Peerawong Werarak, Lauren Laimon, Roslyn Hennessy, Lisa M Frenkel, Patricia Anthony, Brookie M Best, George K Siberry, Mark Mirochnick. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial. The lancet. HIV. 2020 05; 7(5):e322-e331. doi: 10.1016/s2352-3018(20)30038-2. [PMID: 32386720]
  • Xiuhui Li, Hongyan Li, Chuanyun Li, Wei Xia, Ang Li, Weihua Li. Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients. AIDS research and human retroviruses. 2020 04; 36(4):258-259. doi: 10.1089/aid.2019.0274. [PMID: 31958968]
  • David W Haas, Yoninah S Cramer, Catherine Godfrey, Susan L Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert Coombs, Kristine Coughlin, Laura E Moran, David Gingrich, Carmen D Zorrilla, Paxton Baker, Susan E Cohn, Kimberly K Scarsi. Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. Pharmacogenetics and genomics. 2020 04; 30(3):45-53. doi: 10.1097/fpc.0000000000000396. [PMID: 32106141]
  • Kimberly S Collins, Ingrid F Metzger, Brandon T Gufford, Jessica B Lu, Elizabeth B Medeiros, Victoria M Pratt, Todd C Skaar, Zeruesenay Desta. Influence of Uridine Diphosphate Glucuronosyltransferase Family 1 Member A1 and Solute Carrier Organic Anion Transporter Family 1 Member B1 Polymorphisms and Efavirenz on Bilirubin Disposition in Healthy Volunteers. Drug metabolism and disposition: the biological fate of chemicals. 2020 03; 48(3):169-175. doi: 10.1124/dmd.119.089052. [PMID: 31888882]
  • Chengbo Xu, Yijing Xin, Minghua Chen, Mingyu Ba, Qinglan Guo, Chenggen Zhu, Ying Guo, Jiangong Shi. Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root. European journal of medicinal chemistry. 2020 Mar; 189(?):112071. doi: 10.1016/j.ejmech.2020.112071. [PMID: 32004936]
  • Sung-Hsi Huang, Shu-Wen Lin, Sui-Yuan Chang, Ya-Ting Lin, Hsin-Yun Sun, Wen-Chun Liu, Yi-Ching Su, Chien-Ching Hung, Shan-Chwen Chang. Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020 Feb; 53(1):60-68. doi: 10.1016/j.jmii.2018.05.001. [PMID: 29884449]
  • Evelin Dos Santos Martins, Jonata Augusto Oliveira, Taísa Busaranho Franchin, Bruna Cristina Ulian Silva, Caroline Damico Cândido, Rosângela Gonçalves Peccinini. Simple and Rapid Method by Ultra High-Performance Liquid Chromatography (UHPLC) with Ultraviolet Detection for Determination of Efavirenz in Plasma: Application in a Preclinical Pharmacokinetic Study. Journal of chromatographic science. 2020 Jan; 57(10):874-880. doi: 10.1093/chromsci/bmz078. [PMID: 31602469]
  • Nomchenge Yamkelani Mlunguza, Somandla Ncube, Precious Nokwethemba Mahlambi, Luke Chimuka, Lawrence Mzukisi Madikizela. Determination of selected antiretroviral drugs in wastewater, surface water and aquatic plants using hollow fibre liquid phase microextraction and liquid chromatography - tandem mass spectrometry. Journal of hazardous materials. 2020 01; 382(?):121067. doi: 10.1016/j.jhazmat.2019.121067. [PMID: 31476719]
  • Michael J Peluso, Donn J Colby, Suteeraporn Pinyakorn, Sasiwimol Ubolyam, Jintana Intasan, Rapee Trichavaroj, Nitiya Chomchey, Peeriya Prueksakaew, Bonnie M Slike, Shelly J Krebs, Ningbo Jian, Merlin L Robb, Praphan Phanuphak, Nittaya Phanuphak, Serena Spudich, Jintanat Ananworanich, Eugène Kroon. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection. Journal of the International AIDS Society. 2020 01; 23(1):e25444. doi: 10.1002/jia2.25444. [PMID: 31953919]
  • Sheng Sun, Biao Xu, Qiang Zhang, Chang-Song Zhao, Rui Ma, Jie He, Yao Zhang. The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty. Current HIV research. 2020; 18(4):248-257. doi: 10.2174/1570162x18666200510010207. [PMID: 32386494]
  • Qijian Su, Zhenzhen Lu, Yunxia Tang, Suosu Wei, Zhipin Zhou, Feng Jiang. Influence of a herbal preparation on the pharmacokinetics of highly active antiretroviral therapy drugs in rats. Pakistan journal of pharmaceutical sciences. 2020 Jan; 33(1):49-52. doi: NULL. [PMID: 32122830]
  • Jasreen Dhother, Shyamalie Bopitiya, Huda Taha, Satyajit Das. The Effect of Low Dose Oral Vitamin D on Bone Mineral Density Changes in HIV Patients: 36 Months Follow Up. Infectious disorders drug targets. 2020; 20(5):651-658. doi: 10.2174/1871526519666190618160748. [PMID: 31258093]
  • D Mhandire, G Morse, C Maponga, K Mhandire, C Dandara. Plasma efavirenz concentration inversely correlates with increased risk of cytomegalovirus infection in HIV-infected pregnant women. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 2019 Dec; 110(1):10-15. doi: 10.7196/samj.2019.v110i1.14316. [PMID: 31865936]
  • Shakir Adeyinka Atoyebi, Rajith K R Rajoli, Ebunoluwa Adejuyigbe, Andrew Owen, Oluseye Bolaji, Marco Siccardi, Adeniyi Olagunju. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2019 Dec; 140(?):105068. doi: 10.1016/j.ejps.2019.105068. [PMID: 31518681]
  • María Begoña Baza, Adrian Jerónimo, Isabel Río, Carmen Rodriguez, Mar Vera, Victoria Hernando, Jesus Castilla, Jorge Del Romero. Natural Conception is Safe for HIV-Serodiscordant Couples with Persistent Suppressive Antiretroviral Therapy for the Infected Partner. Journal of women's health (2002). 2019 11; 28(11):1555-1562. doi: 10.1089/jwh.2018.7485. [PMID: 31329519]
  • Pedro Ayuso, Megan Neary, Justin Chiong, Andrew Owen. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations. The Journal of antimicrobial chemotherapy. 2019 11; 74(11):3281-3290. doi: 10.1093/jac/dkz329. [PMID: 31369088]
  • Rena C Patel, Randy M Stalter, Katherine K Thomas, Bani Tamraz, Steven W Blue, David W Erikson, Christina J Kim, Edward J Kelly, Kavita Nanda, Athena P Kourtis, Jairam R Lingappa, Nelly Mugo, Jared M Baeten, Kimberly K Scarsi. A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda. AIDS (London, England). 2019 11; 33(13):1995-2004. doi: 10.1097/qad.0000000000002308. [PMID: 31306173]
  • Ingrid F Metzger, Nimita Dave, Yvonne Kreutz, Jessica B L Lu, Raymond E Galinsky, Zeruesenay Desta. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers. Clinical and translational science. 2019 11; 12(6):657-666. doi: 10.1111/cts.12671. [PMID: 31339646]
  • Dhanashree H Surve, Anil B Jindal. Development and validation of reverse-phase high-performance liquid chromatographic (RP-HPLC) method for quantification of Efavirenz in Efavirenz-Enfuvirtide co-loaded polymer-lipid hybrid nanoparticles. Journal of pharmaceutical and biomedical analysis. 2019 Oct; 175(?):112765. doi: 10.1016/j.jpba.2019.07.013. [PMID: 31349211]
  • Nithya Srinivas, Elias P Rosen, William M Gilliland, Martina Kovarova, Leila Remling-Mulder, Gabriela De La Cruz, Nicole White, Lourdes Adamson, Amanda P Schauer, Craig Sykes, Paul Luciw, J Victor Garcia, Ramesh Akkina, Angela D M Kashuba. Antiretroviral concentrations and surrogate measures of efficacy in the brain tissue and CSF of preclinical species. Xenobiotica; the fate of foreign compounds in biological systems. 2019 Oct; 49(10):1192-1201. doi: 10.1080/00498254.2018.1539278. [PMID: 30346892]
  • Melanie R Nicol, Katelyn A Pastick, Joneé Taylor, Olivie C Namuju, Joshua Rhein, Darlisha A Williams, David B Meya, David R Boulware, Robert Lukande. Cerebrospinal Fluid and Brain Tissue Penetration of Tenofovir, Lamivudine, and Efavirenz in Postmortem Tissues with Cryptococcal Meningitis. Clinical and translational science. 2019 09; 12(5):445-449. doi: 10.1111/cts.12661. [PMID: 31207069]
  • Kimberly K Scarsi, Yoninah S Cramer, Susan L Rosenkranz, Francesca Aweeka, Baiba Berzins, Robert W Coombs, Kristine Coughlin, Laura E Moran, Carmen D Zorrilla, Victor Akelo, Mariam Aziz, Ruth K Friedman, David Gingrich, Shobha Swaminathan, Catherine Godfrey, Susan E Cohn. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. The lancet. HIV. 2019 09; 6(9):e601-e612. doi: 10.1016/s2352-3018(19)30155-9. [PMID: 31498109]
  • Catriona Waitt, Catherine Orrell, Stephen Walimbwa, Yashna Singh, Kenneth Kintu, Bryony Simmons, Julian Kaboggoza, Mary Sihlangu, Julie-Anne Coombs, Thoko Malaba, Josaphat Byamugisha, Alieu Amara, Joshua Gini, Laura Else, Christie Heiburg, Eva Maria Hodel, Helen Reynolds, Ushma Mehta, Pauline Byakika-Kibwika, Andrew Hill, Landon Myer, Mohammed Lamorde, Saye Khoo. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS medicine. 2019 09; 16(9):e1002895. doi: 10.1371/journal.pmed.1002895. [PMID: 31539371]
  • Archana Asundi, Yvonne Robles, Tyler Starr, Alan Landay, Jennifer Kinslow, Joshua Ladner, Laura White, Rebeca M Plank, Kathleen Melbourne, Daniel Weisholtz, Monica Bennett, Hong Pan, Emily Stern, Alexander Lin, Daniel R Kuritzkes, Nina H Lin. Immunological and Neurometabolite Changes Associated With Switch From Efavirenz to an Integrase Inhibitor. Journal of acquired immune deficiency syndromes (1999). 2019 08; 81(5):585-593. doi: 10.1097/qai.0000000000002079. [PMID: 31045650]
  • Kristine M Erlandson, Long Zhang, Derek K Ng, Keri N Althoff, Frank J Palella, Lawrence A Kingsley, Lisa P Jacobson, Joseph B Margolick, Jordan E Lake, Todd T Brown. Risk Factors for Falls, Falls With Injury, and Falls With Fracture Among Older Men With or at Risk of HIV Infection. Journal of acquired immune deficiency syndromes (1999). 2019 08; 81(4):e117-e126. doi: 10.1097/qai.0000000000002074. [PMID: 31242143]
  • Adam R Cassidy, Paige L Williams, Jean Leidner, Gloria Mayondi, Gbolahan Ajibola, Joseph Makhema, Penny A Holding, Kathleen M Powis, Oganne Batlang, Chipo Petlo, Roger Shapiro, Betsy Kammerer, Shahin Lockman. In Utero Efavirenz Exposure and Neurodevelopmental Outcomes in HIV-exposed Uninfected Children in Botswana. The Pediatric infectious disease journal. 2019 08; 38(8):828-834. doi: 10.1097/inf.0000000000002332. [PMID: 30985518]
  • Alexey M Petrov, Natalia Mast, Yong Li, Irina A Pikuleva. The key genes, phosphoproteins, processes, and pathways affected by efavirenz-activated CYP46A1 in the amyloid-decreasing paradigm of efavirenz treatment. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019 08; 33(8):8782-8798. doi: 10.1096/fj.201900092r. [PMID: 31063705]
  • Oladele Vincent Adeniyi, Chikwelu Larry Obi, Daniel Ter Goon, Benson Iweriebor, Anthony Idowu Ajayi, John Lambert, Anthony Okoh. HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2019 08; 117(?):89-95. doi: 10.1016/j.jcv.2019.06.003. [PMID: 31255794]